RTS,S today and tomorrow's science

Nginache Nampota Nkomba; Cristiana Cairo; Miriam K Laufer

doi:10.1016/j.chom.2022.04.004

RTS,S today and tomorrow's science

Cell Host Microbe. 2022 May 11;30(5):604-606. doi: 10.1016/j.chom.2022.04.004.

Authors

Nginache Nampota Nkomba¹, Cristiana Cairo², Miriam K Laufer³

Affiliations

¹ Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
² Institute for Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: ccairo@ihv.umaryland.edu.
³ Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mlaufer@som.umaryland.edu.

Abstract

The first malaria vaccine has been recently approved for children living in malaria-endemic areas. While this is long-awaited and welcome news, the modest efficacy of the vaccine highlights several areas that require further attention. Here, we describe the likely impact of the vaccine and where clinical and basic discovery research will still be required.

MeSH terms

Child
Humans
Infant
Malaria Vaccines*
Malaria* / epidemiology
Malaria* / prevention & control
Malaria, Falciparum* / epidemiology
Malaria, Falciparum* / prevention & control
Plasmodium falciparum

Substances

Malaria Vaccines

Abstract

MeSH terms

Substances

Grants and funding